Revised：September 2022 (1st version)

Standard Commodity Classification No. of Japan
875200

-Kampo product-

SG-05T

OHSUGI Anchusanryo
Extract T Tablets

(Anchusan)

Storage：Store at room temperature

Shelf Life：3 years

	Approval No.	Date of Initial Marketing in Japan
Tablets	16100AMZ04185000	October 1986

3. COMPOSITION AND PRODUCT DESCRIPTION

3.1 Composition

Brand name	OHSUGI Anchusanryo Extract T Tablets	
Active ingredient	The daily dose of this product, 9 tablets, contains 1.0 g of the dried extract (Anchusanryo extract) from the following mixed crude drugs.	
	JP Cinnamon Bark	4 g
	JP Corydalis Tuber	3 g
	JP Oyster Shell	3 g
	JP Amomum Seed	1 g
	JP Glycyrrhiza	1 g
	JP Alpinia Officinarum Rhizome	1 g
	JP Fennel	1.5 g
	JP ：Japanese Pharmacopoeia	
Excipients	Microcrystalline Cellulose, Magnesium Aluminometasilicate, Carmellose Calcium, Magnesium Stearate, Hypromellose, Titanium Oxide, FD&C Yellow No.6 [Sunset Yellow FCF], FD&C Blue No.1 [Brilliant Blue FCF] and FD&C Red No.3 [Erythrosine]	

3.2 Product Description

Brand name	OHSUGI Anchusanryo Extract T Tablets		
Dosage form	Film-coated tablets		
Tone	Light brown-colored film-coated tablets		
Form	Front	Back	Side
			
Diameter	About 9.0 mm		
Thickness	About 5.4 mm		
Weight	About 310 mg		
ID Code	ＳＧ－０５Ｔ		

4. INDICATIONS

The following symptoms in patients who have a thin body habitus and who have a tendency to have relaxed abdominal muscles, with stomach or abdominal pain, sometimes accompanied by heartburn, belching, anorexia, or nausea:

Neurotic gastritis, chronic gastritis, and gastric atony

6. DOSAGE AND ADMINISTRATION

The usual adult dose is 9 tablets/day orally in 2 or 3 times before or between meals. The dosage may be adjusted according to the patient's age, body weight, and symptoms.

8. IMPORTANT PRECAUTIONS

8.1 When this product is used, the patient's "SHO" (constitution/symptoms) should be taken into consideration. The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

8.2 Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc. [See Sections 10.2, 11.1.1, 11.1.2]

8.3 When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs.

SHO: The term "SHO" refers to a particular pathological status of a patient evaluated by the Kampo diagnosis, and is patterned according to the patient's constitution, symptoms, etc. Kampo products should be used after confirmation that it is suitable for the identified "SHO" of the patient.

9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS

9.5 Pregnant Women

This product should be used in pregnant women or women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

9.6 Breast-feeding Women

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered.

9.7 Pediatric Use

No clinical studies have been conducted in children.

9.8 Geriatric Use

Since the physiological functions are generally decreased in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

10. INTERACTIONS

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Glycyrrhiza-containing preparations Shakuyakukanzoto Hochuekkito Yokukansan, etc. Preparations containing glycyrrhizic acid and its salts Monoammonium Glycyrrhizinate/Glycine/ L-cysteine Monoammonium Glycyrrhizinate/Glycine/ DL-Methionine combination tablets, etc. [See Sections 8.2, 11.1.1, 11.1.2]	Pseudoaldosteronism is likely to occur. As a result of hypokalaemia, myopathy is likely to occur.	Since glycyrrhizic acid has an accelerating effect on potassium excretion in the renal tubules, an acceleration of decrease in the serum potassium level has been suggested.

11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

11.1 Clinically Significant Adverse Reactions

11.1.1 Pseudoaldosteronism (frequency unknown)

Pseudoaldosteronism such as hypokalaemia, blood pressure increased, retention of sodium/body fluid, edema, and body weight gain may occur. Patients should be carefully monitored (e.g., measurement of serum potassium levels), and if any abnormalities are observed, administration should be discontinued, and appropriate measures such as administration of potassium preparations should be taken. [See Sections 8.2, 10.2]

11.1.2 Myopathy (frequency unknown)

Myopathy may occur as a result of hypokalaemia. Patients should be carefully monitored, and if any abnormalities such as feelings of weakness, muscle cramp in extremities, or paralysis are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken. [See Sections 8.2, 10.2]

11.2 Other Adverse Reactions

	Frequency unknown
Hypersensitivity	Rash, redness, pruritus, etc.

20. PRECAUTIONS FOR HANDLING

20.1 To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.

20.2 Avoid moisture, especially after opening, and handle with care.

20.3 Since this product is made from crude drugs, the color of the product may vary.

22. PACKAGING

882 tablets（3 tablets × 294 packets） ［Sachet］
252 tablets（3 tablets × 84 packets） ［Sachet］

24. REFERENCE REQUEST AND CONTACT INFORMATION

Dep. of PMS Information,
Ohsugi Pharmaceutical Co., Ltd.
1-8-6, Yamasaka, Higashisumiyoshi-ku, Osaka 546-0035
06-6629-9058

26. MARKETING AUTHORIZATION HOLDER, etc.

26.1 Marketing Authorization Holder

Takasago Pharmaceutical Co., Ltd.
2-1-20, Tennojichominami Abeno-ku, Osaka 545-0002

26.2 Publisher

Ohsugi Pharmaceutical Co., Ltd.
1-1-2, Tennojichominami Abeno-ku, Osaka 545-0002